AngioDynamics Inc. designs, manufactures and sells a wide range of medical, surgical and diagnostic devices. The devices are generally used in minimally invasive, image-guided procedures. AngioDynamics product offerings fall within three Global Business Units, namely Oncology/Surgery, Endovascular Therapies and Vascular Access. Endovascular Therapies product offerings support the medical areas of Thrombus Management, Atherectomy, Peripheral Products and Venous Insufficiency. The Thrombus Management portfolio includes the proprietary AngioVac venous drainage cannula and circuit as well as catheter directed thrombolytic devices. Vascular Access arm offers advanced imaging equipment to guide the placement of catheters that primarily deliver short-term drug therapies. IGVA procedures include the placement of Peripherally Inserted Central Catheters lines, implantable ports and central venous catheters. Oncology/Surgery division includes Microwave Ablation, Radiofrequency Ablation and NanoKnife product lines....
+See More2018-10-30 10:41:00 Tuesday ET

Personal finance author Ramit Sethi suggests that it is important to invest in long-term gains instead of paying attention to daily dips and trends. It
2023-11-28 11:35:00 Tuesday ET

David Colander and Craig Freedman argue that economics went wrong when there was no neoclassical firewall between economic theories and policy reforms. D
2018-10-03 11:37:00 Wednesday ET

Fed Chair Jerome Powell sees a remarkably positive outlook for the U.S. economy right after the recent interest rate hike as of September 2018. He humbly su
2018-10-25 10:36:00 Thursday ET

Trump tariffs begin to bite U.S. corporate profits from Ford and Harley-Davidson to Caterpillar and Walmart etc. U.S. corporate profit growth remains high a
2025-06-21 10:25:00 Saturday ET

Former New York Times science author and Harvard psychologist Daniel Goleman explains why emotional intelligence can serve as a more important critical succ
2023-01-03 09:34:00 Tuesday ET

USPTO fintech patent protection and accreditation As of early-January 2023, the U.S. Patent and Trademark Office (USPTO) has approved